### **Company Overview** Jubilant Pharmova Ltd is a **diversified global pharmaceutical company** with an integrated end-to-end platform across **six core business segments**: 1. **Radiopharma** 2. **Allergy Immunotherapy** 3. **CRDMO (Contract Research, Development, and Manufacturing Organization)** 4. **CDMO Sterile Injectables** 5. **Generics** 6. **Proprietary Novel Drugs** Headquartered in India, the company operates with a strong global footprint, serving over **140 countries**, and employs approximately **5,500 people**, with significant operations in the U.S., Canada, and Europe. Jubilant is widely recognized as a **"Partner of Choice"** by leading global pharmaceutical and biotech companies due to its **vertical integration, innovation, and regulatory excellence**. With FY24 revenue of ₹6,703 crore (~$800 million), Jubilant has established itself as a **market leader in multiple high-barrier specialties** and is executing an aggressive long-term vision (Vision 2030) to **double revenue**, expand EBITDA margins, and become **net debt-free**. --- ### **Core Business Segments & Strategic Highlights** #### **1. Radiopharma** - **Market Leadership**: Leading manufacturer of radiopharmaceuticals in the U.S. and second-largest radiopharmacy network with **45 sites (as of Oct 2025; previously 46)** across the U.S., serving over 1,800 hospitals. - **USP 825 Compliance**: All radiopharmacies compliant, achieving **>99% on-time dose delivery**. - **Key Products & Leadership**: - **Ruby-Fill®**: Global innovation leader in **cardiac PET imaging**. - 25% market share in a **$180 million, 12% CAGR market**. - Generators have **7-week lifespan** vs. peers’ 6 weeks; better consistency and no additional shielding. - Deployed in **mobile settings** to increase access in rural areas; installations up 24% YoY. - Backed by **AI-enabled 3D cardiac blood flow quantification**, reducing processing time from 2 hours to <75 seconds. - **SPECT Imaging**: Market leader in **MAA, DTPA, Sulphur Colloid**, and **HICON® I-131**. - **No competition** in U.S. for **Iodine-131** used in thyroid cancer therapy. - **Product Pipeline & TAM Expansion**: - Pipeline unlocks **$550 million in new TAM** starting FY27. - Expected **peak sales of $120 million** from 9 new product launches: - FY27: 2 launches ($20M peak) - FY28: 3 launches ($60M peak) - FY29: 4 launches ($40M peak) - **Therapeutic Pipeline**: - **I-131 MIBG (neuroblastoma)**: Phase II OPTIMUM trial completed (Apr 2024); FDA data submission expected H2 FY26, launch in FY27. - **Infrastructure Growth**: - **$50 million investment** to expand PET radiopharmacy network from **3 to 9 sites**, including 6 new U.S. locations. --- #### **2. Allergy Immunotherapy** - **Sole supplier of venom immunotherapy** in the U.S. and Canada; **#2 player** in allergenic extract market. - Operates under the **HollisterStier brand** (100+ years of legacy). - **Portfolio**: - **200+ allergen extracts** and **6 venom products**. - Skin testing devices like **ComforTen, Quintest, Quintip**. - **Strategic Priorities**: - Expand U.S. **BeeAware awareness campaign**. - Launch **ultra-filtered dog dander** for consistent dosing. - International expansion in **EU, MEA, APAC**, via partnerships. - **Revenue & Margin Target**: - Targeting **1.5x revenue growth from FY24 level of ₹6,786 million by FY30**, with **EBITDA margins of 35–40%**. --- #### **3. CRDMO (Contract Research, Development, and Manufacturing Organization)** - **India’s leader in Integrated Drug Discovery**, having delivered **85+ programs**. - Strengths: - Fully **integrated chemistry platform** from **milligram to multi-ton scale**. - **5x increase** in revenue from large pharma clients in past year. - Customer base includes **8 of top 20 global pharma companies**. - Serve 40+ clients; **750 scientists** in chemistry, **~350 in discovery**. - **API Leadership**: - Offers **~100 APIs** across CNS, CVS, anti-infectives, anti-diabetics. - Leaders in **Carbamazepine, Oxcarbazepine, Pinaverium, Risperidone, Donepezil, Lamotrigine, Valsartan**. - **Strategic Expansion**: - **API business transferred to Jubilant Biosys** (subsidiary) to consolidate CRDMO operations and improve efficiency. - Focus on **CDMO services**, **custom manufacturing**, and **innovation-led affordability**. - **"China Plus One" Strategy**: Diversifying supply chain, increasing backward integration, reducing dependence on Chinese raw materials. - **Growth Target**: Triple **Drug Discovery Services revenue** from **₹4,485 million (FY24)** to **over ₹13,455 million by FY30**, with **>25% EBITDA margin**. --- #### **4. CDMO Sterile Injectables** - **North American leader**, serving **5 of top 20 global pharma companies** and **>25 global clients**. - **Facilities**: Spokane, WA and Montreal, Canada – **US FDA, PMDA, KFDA, ANVISA, MHRA approved**. - **Services**: Liquid and freeze-dried fill-finish, ophthalmics (liquids, ointments), biologics, ampoules. - **Expansion**: - **$285 million expansion in Spokane** with **Lines 3 and 4** (isolator technology). - Line 3: **commercial production from FY26**, full utilization in 3 years. - Line 4: **onstream FY28**. - Capacity to **double**, adding ~160,000 sq. ft., lyophilizers, ultra-cold storage. - **U.S. Government IBX consortium** and **DPAS rating** to expedite critical equipment procurement. - **Commercial Model**: - **Dual strategy**: Key Account Directors (farming) + Business Development (hunting). - **92% retention rate**, 6+ year relationships with top 10 clients. - **Growth Target**: - More than double revenue from **₹11,171 million (FY24)** by FY30, with **>25% EBITDA**. --- #### **5. Generics** - Offers formulations in **CVD, CNS, GI, anti-infectives, multi-specialty**. - **India Branded Generics**: Focused on **dyslipidemia (Jubira), hypertension (Telmi), diabetes (Jubiglim, Dapaease), and weight management (DM Care)**. - **Global Reach**: Over 50 countries; **101 ANDAs filed in US**, 70 approved; high approval rates in EU, UK, Canada. - **Strategic Shift (U.S.)**: - Exited U.S. in-house manufacturing (Q1 FY25); shifted profitable assets to **contract manufacturers (CMOs)**. - Sourcing from **Roorkee, India (FDA-approved)**. - Improved **gross margins and profitability** (3% EBITDA achieved in FY25). - **Growth Plan**: Launch **6–8 products/year in US and key non-U.S. markets** (UK, UAE) via in-licensing and development. - **Vision 2030**: Double revenue from **₹7,746 million (FY24)**, maintain **15–17% EBITDA margin**. --- #### **6. Proprietary Novel Drugs (Jubilant Therapeutics)** - **Clinical-stage biopharma** subsidiary developing **oral precision therapies** for oncology and autoimmune diseases. - **Lead Programs**: - **JBI-802 (CoREST/HDAC6 inhibitor)**: - In **Phase II trials** for Essential Thrombocythemia post-myelofibrosis. - Phase I showed anti-tumor activity in NSCLC patients. - **JBI-778 (brain-penetrant PRMT5 inhibitor)**: - **IND approved (Aug 2024)**; global trials underway. - Trials planned at **MSK, Christ Hospital, Dana-Farber**. - **Scientific Advisory Board**: Experts from **Memorial Sloan-Kettering, Dana-Farber, Boston Children’s**, and **Tel Aviv University**. - **Orphan Drug Designations**: - **JBI-802**: AML, SCLC. - **JBI-778**: Glioblastoma. - **Proprietary TIBEO Platform**: Therapeutic Index and Brain Exposure Optimisation for challenging targets. - **R&D Model**: Cost-efficient, in-house discovery; **two programs acquired/partnered**, one by **Blueprint Medicines (NASDAQ: BPMC)**. --- ### **Strategic Enablers** #### **1. Technology & Innovation** - **AI/ML SaaS Platform – TrialStat®**: - **TrialStat Orbit** (eDB capture) - **TrialStat CTMS** (trial management) - **TrialStat Portal** (analytics) - **AI in Imaging**: 3D blood flow quantification for **Ruby-Fill®**. - **Digital Integration**: SAP, automation, and digital R&D labs to enhance speed. #### **2. Global Expansion** - **Key Markets**: UK subsidiary (direct presence, MHRA approvals for 23 products), UAE subsidiary. - **International Generics**: Build **3–4 key B2B2C markets**. - **Radiopharma & Allergy**: Expansion in **EU, APAC, MEA, Latin America**. #### **3. Regulatory & Compliance Excellence** - Facilities approved by **U.S. FDA, Health Canada, ANVISA, PMDA, MHRA**. - **USP 825 compliant radiopharmacies**, **VAI rating** for Roorkee API plant (Mar 2023). - Successful FDA audits despite past OAI at Montreal CDMO site. #### **4. Supply Chain Resilience** - **"China Plus One" strategy**. - **Backward integration** in API and KSM production. - Use of **in-house ethanol, picolines, pyridines** as feedstock. #### **5. Capital Expenditure & Investments** - **$285M** in Spokane CDMO expansion. - **$150M** U.S. government funding under BARDA. - **$50M** for radiopharmacy expansion. - **1.7% stake in O2 Renewable Energy** to secure green power. #### **6. M&A & Partnerships** - **Pierre Fabre Strategic Partnership**: - Acquired R&D center in **Saint-Julien, France**. - Expanded into **mAbs, ADCs**, biologics. - Added $1.4 billion to TAM. - **SOFIE Biosciences Investment (25.8% stake to be sold)**: $143 million expected in divestment proceeds. - **Jasmin (New Co)**: 80% acquisition to build European biologics base. --- ### **Competitive Advantages** - **Vertical Integration**: Own APIs, manufacturing, R&D, distribution. - **High Entry Barriers**: Sterile fill tech, radiopharmacy licenses, biologics complexity. - **Long Client Tenures**: >5 years with top 10 customers; **24–36 months customer lock-in**. - **Strong IP & Regulatory Strategy**: Patents in U.S., EU, PCT; **orphan drug designations**. - **Onshore Manufacturing**: Critical in wake of **U.S. BioSecure Act, tariff risks, and China exit trends**. ---